14 June Duke-Margolis workshop + A taxonomy for non-traditional (non-Fleming) antimicrobials

Dear All: (18 June addendum: the materials from the meeting are now posted!)

First, planning continues apace for the 14 June Duke-Margolis workshop on non-traditional products. There is now a link for registration, confirmation that the event is going to be webcast, and a draft agenda. Mark your calendar now to attend either in person or via the webcast!

Second, I would like to expand a bit on my very brief 23 Apr 2018 post on the discussion of non-traditional products at the CARB-X– and GARDP-sponsored ECCMID symposium on regulatory issues. The full talk can be found here and was based on conversations with multiple colleagues (see list on slide 4). The key ideas are:

1. “Non-traditional” covers a lot of territory and it is helpful to refine the idea by envisioning a continuum for antimicrobial therapeutic products that runs from Fleming to non-Fleming products:

  • Fleming: A product that is like a penicillin in that it has the spectrum for a defined syndrome and the speed required to be suitable as standalone therapy (SSSS, if you like acronyms). Importantly, this means that standard non-inferiority trial designs can be used as the basis for registration.
  • Non-Fleming = Everything else = Non-traditional. This can include phage, antibodies, small molecules, large molecules, microbiome … it’s non-Fleming because it lacks one or more of the spectrum-syndrome-speed-standalone properties of a Fleming .

2. Digging more deeply, it then becomes helpful to replace the ambiguous terms alternative to antibioticspotentiator, and enhancer with four functional archetypes for the non-Fleming therapeutic products: Create, Transform, Enhance, and Restore:

Picture

To emphasize, this taxonomy of non-Fleming antimicrobial products is entirely functional:  physical nature of the product (large, small, phage, etc.) is not relevant! Rather, the behavior of the product defines the opportunities it brings and the challenges it faces. You should review the entire talk, but here’s a quick summary:

  • The archetypes Create and Enhance have the advantage of often being really novel, but the challenges of often being narrow, not standalone, requiring superiority study designs, and not being able to use an MIC as the basis for PK-PD thinking.
  • Conversely, the archetypes Transform and Restore have the advantages of leveraging a known component, of being able to leverage an MIC for PK-PD, and often being suitable for standalone development despite the challenge of sometimes being very narrow in terms of spectrum.

3. Agents for prevention are a distinct category and the Fleming/Non-Fleming idea is really not relevant. Instead, the problem is the general challenge of showing an advantage over best Standard of Care. See the slide deck for a specific example. 

OK, that’s enough for now … I look forward to the conversation on 14 June where we will hopefully expand further on the challenges around non-traditional products!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top